Hepatitis C treatment: latest news

Hepatitis C treatment resources

  • Hepatitis C treatment

    Effective treatments are available for hepatitis C. This field is evolving rapidly and standards of care are changing. The newest drugs can cure most people with hepatitis...

    From: Booklets

    Information level Level 2
  • Medications for hepatitis C

    The old standard of care for hepatitis C treatment for all HCV genotypes was pegylated interferon and ribavirin. Interferon works by stimulating immune system activity against HCV. There...

    From: Booklets

    Information level Level 2
  • Hepatitis C treatment for people with co-infection

    Current guidelines recommend that you start hepatitis C treatment if you have HIV and HCV co-infection with moderate or worse liver fibrosis (stage F2 to F4) and...

    From: Booklets

    Information level Level 2
  • Hepatitis C

    Hepatitis C virus (HCV) is chiefly transmitted by blood-to-blood contact. When the blood of a person with hepatitis C enters the bloodstream of another person,...

    From: Factsheets

    Information level Level 2
  • Hepatitis C

    Hepatitis C is a serious infection caused by a virus.It damages the liver, which performs essential functions in the body.Some people have hepatitis C for...

    From: The basics

    Information level Level 1
  • Hepatitis C treatment

    Deciding on the best time to take treatment for hepatitis C is not straightforward.It’s important to get support and advice to help you with this...

    From: The basics

    Information level Level 1
  • Hepatitis C virus treatment

    The current preferred treatment regimen for HCV infection is a combination of peginterferon alfa (given by injection) plus ribavirin (given orally). Interferons are human proteins that...

    From: HIV treatments directory

    Information level Level 4

Hepatitis C treatment features

Hepatitis C treatment in your own words

Hepatitis C treatment news from aidsmap

More news

Hepatitis C treatment news selected from other sources

  • Morocco without hepatitis C in 2020

    The Moroccan minister of health said “Morocco without hepatitis C” is the aim for the North African country. The announcement came as Houceine El Ouardi announced a Moroccan generic brand medication for Hepatitis C will be available for purchase from December 10.

    27 November 2015 | Morocco World News
  • UK: Hep C patients to get NHS access to three new therapies

    Patients with hepatitis C living in England and Wales could get ‘routine’ access to three new treatments - Gilead’s Harvoni, AbbVie’s Viekirax and Bristol-Myers Squibb’s Daklinza - after cost-regulators NICE approved their use on the National Health Service.

    27 November 2015 | Pharma Times
  • Pricey HCV Drugs Worth the Cost

    Reductions in disease complications and quality health gains offset drug costs in simulation model.

    27 November 2015 | MedPage Today
  • The Medicines Patent Pool Signs Licence with Bristol-Myers Squibb to Increase Access to Hepatitis C Medicine Daclatasvir

    The royalty-free licence will enable generic manufacture of daclatasvir for sale in 112 low- and middle-income countries (LMICs), 76 of which are World Bank classified middle-income nations. Nearly two-thirds of all patients living with hepatitis C in the LMICs reside in the territory covered by this agreement.

    23 November 2015 | Medicines Patent Pool
  • Why We Should Be Willing to Pay for Hepatitis C Treatment

    The overall budget needed to treat HCV with these new treatments is not huge and is reasonable when compared with the cost of HIV treatment. The discounted lifetime cost of treating 1 person with HIV in the U.S. is $315,000 in 2014 U.S. dollars. The corresponding cost of curing HCV with oral DAAs is $58,000 -- which is only 18 percent of the total HIV treatment cost. Note these two unlike words: treating and curing.

    23 November 2015 | Huffington Post
  • Leading liver doctors: Hepatitis C patients must be treated

    Many insurers – both private and public – are delaying access to new HCV treatments to patients until their disease has progressed and the liver is further damaged. There is no medical evidence to justify that position and much to justify treating all patients.

    17 November 2015 | American Association for the Study of Liver Diseases press release
  • Pricing Pressures: How the Business of Medicine Affects the Price of Therapy

    Through a series of interviews with HCV Next, the manufacturers addressed the basics of how they arrived at the price for the drugs and combinations. Insurance experts discussed the specifics of coverage and how the Affordable Care Act is changing the game. Payers offered insight on their own role in the increasingly competitive arena.

    16 November 2015 | Healio HCV Next
  • Medicare will spend $9 billion on Hepatitis-C drugs this year

    Medicare spending on breakthrough medications for hepatitis C will nearly double this year, passing $9 billion, according to new government figures. That’s raising insurance costs for all beneficiaries, whether or not they have the liver-wasting viral disease.

    16 November 2015 | PBS NewsHour
  • U.S. FDA approves new indications for Harvoni®, Gilead’s once-daily single tablet regimen for chronic hepatitis C

    Label expanded to include patients with genotypes 4, 5 and 6 and patients co-infected with HIV.

    13 November 2015 | Gilled press release
  • The Medicines Patent Pool Expands Mandate to Hepatitis C and Tuberculosis Treatment

    The UNITAID Executive Board, meeting November 4-5 in Geneva, approved the MPP’s proposals to improve access to both life-saving direct acting antivirals (DAAs) to treat hepatitis C and new and re-purposed medicines for tuberculosis.

    09 November 2015 | Medicines Patent Pool
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.